Search results
Pages
-
- Time trends in the treatment and survival of 5036 Uveal melanoma patients in The Netherlands over a 30-year period
-
- Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nationwide cohort of advanced melanoma patients in the Netherlands
-
- A survival tree of advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors
-
- Health-state utilities in long-term advanced melanoma survivors comparable with the general population
-
- PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer
-
- Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
-
- Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery
-
- Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
-
- Trends in incidence and survival of 1496 patients with mucosal melanoma in the Netherlands (1990-2019)
-
- Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma